Navigation Links
New way to diagnose Alzheimer's disease promises earlier treatment
Date:9/17/2007

Physicians may be able to detect and treat Alzheimers Disease (AD) in its earliest stages, when patients are experiencing only mild degrees of cognitive impairment, thanks to new diagnostic criteria proposed by an international group of researchers.

Published in Lancet Neurology, the development of new guidelines was co-led by Dr. Howard Feldman, head of the Div. of Neurology in the University of British Columbias Faculty of Medicine. Feldman, who directs the Clinic for Alzheimers Disease and Related Disorders at Vancouver Coastal Health, co-authored the paper with French researcher Dr. Bruno Dubois and investigators from countries that include Japan, the U.S. and England. Feldman is a member of Vancouver Coastal Health Research Institute (VCHRI).

The proposed criteria are based on examining the structure and function of the brain using advanced brain imaging techniques as well as looking at spinal fluid for the imprint of the disease. Early detection will allow researchers to test vaccines that might be used preventively or to treat fully affected individuals, or other drug treatments that are directed at the earliest stages of the disease the best time to reduce symptoms.

Existing criteria, established in 1984, involve a two-step approach of evaluating functional disability and then looking for a cause, meaning diagnosis and treatment is delayed until patients have significant dementia symptoms. Integrating the profound neurobiological advances of the last 20 years allow for diagnoses based on more than declining functional ability, says Feldman, a senior investigator with the Brain Research Centre (BRC) at UBC Hospital. We now have advanced diagnostic tools distinctive and reliable biological indicators that can be detected before the patient crosses the dementia threshold of disability.

The new criteria the researchers are proposing to the scientific community via the article represent a significant shift and will direct scientists and
'/>"/>

Contact: Hilary Thomson
Hilary.thomson@ubc.ca
604-822-2644
University of British Columbia
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. How to diagnose heart failure?
2. Pain-Free Heart Attacks Often Misdiagnosed
3. New technique to diagnose heart disease
4. Blood test diagnoses heart failure in short time
5. Heart disease diagnosed by dentist?
6. A Simple Exercise Can Uncover Undiagnosed Asthma
7. Breast Cancer Diagnosed Late In Men
8. Imaging Modality That Might Help Diagnose Depression
9. Restless leg syndrome may remain under-diagnosed in many
10. Stroke In The Right-Brain Can Remain Undiagnosed
11. Eye Diseases Diagnosed Through Genetical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Fights the Abortion Bailout by Supporting the Nelson-Hatch-Casey Amendment 2Health News:Patriot Scientific Corporation Announces New Director 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 1Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 2Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 3Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 1Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 1Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 3
Other Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7